Our Trials

We are currently enrolling patients in our Phase 3 MOVE study for palovarotene in fibrodysplasia ossificans progressiva (FOP), and we plan to initiate our first study in multiple osteochondromas (MO) in early 2018.

Fibrodysplasia Ossificans Progressiva

FOP is an ultra-rare, genetic, chronic disease that causes bone growth in muscles, tendons and soft tissue and leaves most affected individuals confined to a wheelchair by the third decade of their life.